Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

Biykem Bozkurt, Guillermo Torre-Amione, Marshelle Smith Warren, James Whitmore, Ozlem Z. Soran, Arthur M. Feldman, Douglas L. Mann

Research output: Contribution to journalArticle

335 Scopus citations

Abstract

Background - Previously, we showed that tumor necrosis factor (TNF) antagonism with etanercept, a soluble TNF receptor, was well tolerated and that it suppressed circulating levels of biologically active TNF for 14 days in patients with moderate heart failure. However, the effects of sustained TNF antagonism in heart failure are not known. Methods and Results - We conducted a randomized, double-blind, placebo-controlled, multidose trial of etanercept in 47 patients with NYHA class III to IV heart failure. Patients were treated with biweekly subcutaneous injections of etanercept 5 mg/m2 (n = 16) or 12 mg/m2 (n = 15) or with placebo (n = 16) for 3 months. Doses of 5 and 12 mg/m2 etanercept were safe and well tolerated for 3 months. Treatment with etanercept led to a significant dose-dependent improvement in left ventricular (LV) ejection fraction and LV remodeling, and there was a trend toward an improvement in patient functional status, as determined by clinical composite score. Conclusion - Treatment with etanercept for 3 months was safe and well-tolerated in patients with advanced heart failure, and it resulted in a significant dose-dependent improvement in LV structure and function and a trend toward improvement in patient functional status.

Original languageEnglish
Pages (from-to)1044-1047
Number of pages4
JournalCirculation
Volume103
Issue number8
DOIs
StatePublished - Feb 27 2001
Externally publishedYes

Keywords

  • Cytokines
  • Growth substances
  • Heart failure
  • Myocardial contraction
  • Tumor necrosis factor

Fingerprint Dive into the research topics of 'Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure'. Together they form a unique fingerprint.

  • Cite this